Mild cognitive impairment pipeline assessment by drug target published

cognitive-impairment WASHINGTON, D.C.: Market research titled Mild Cognitive Impairment – Pipeline Review, H2 2015 is a report providing data and information that helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on Mild Cognitive Impairment pipeline spread across 93 pages, analyzing 11 companies, 21 drug profiles and supported with 28 tables and 15 figures is now available.

Full story covered in the Dementia Business Weekly.